HK1133257A1 - - Google Patents
Info
- Publication number
- HK1133257A1 HK1133257A1 HK10100267.4A HK10100267A HK1133257A1 HK 1133257 A1 HK1133257 A1 HK 1133257A1 HK 10100267 A HK10100267 A HK 10100267A HK 1133257 A1 HK1133257 A1 HK 1133257A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- prodrugs
- salts
- methods
- hydrates
- intermediates
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 abstract 5
- 229940002612 prodrug Drugs 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- -1 phosphate ester Chemical class 0.000 abstract 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86672206P | 2006-11-21 | 2006-11-21 | |
PCT/US2007/085313 WO2008064274A1 (en) | 2006-11-21 | 2007-11-20 | Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1133257A1 true HK1133257A1 (zh) | 2010-03-19 |
Family
ID=39276176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10100267.4A HK1133257A1 (zh) | 2006-11-21 | 2010-01-11 |
Country Status (9)
Country | Link |
---|---|
US (8) | US8163902B2 (zh) |
EP (2) | EP2078026B1 (zh) |
JP (1) | JP5264759B2 (zh) |
AT (1) | ATE540041T1 (zh) |
CA (1) | CA2673137C (zh) |
DK (1) | DK2078026T3 (zh) |
ES (1) | ES2380551T3 (zh) |
HK (1) | HK1133257A1 (zh) |
WO (1) | WO2008064274A1 (zh) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS53109B (en) * | 2003-07-30 | 2014-06-30 | Rigel Pharmaceuticals Inc. | 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES |
NZ563454A (en) | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
CA2642211C (en) * | 2006-02-17 | 2012-01-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
EP2054422B1 (en) | 2006-07-20 | 2017-06-14 | Debiopharm International SA | Acrylamide derivatives as fab i inhibitors |
CA2673125C (en) | 2006-10-19 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
ES2380551T3 (es) | 2006-11-21 | 2012-05-16 | Rigel Pharmaceuticals, Inc. | Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
CA2986640C (en) | 2008-06-27 | 2019-03-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
AP2744A (en) | 2008-07-28 | 2013-09-30 | Pfizer | Phenanthrenone compounds, compositions and methods |
EP2341052A4 (en) * | 2008-09-05 | 2011-10-12 | Shionogi & Co | RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT |
BRPI0913457B8 (pt) | 2008-09-18 | 2021-08-31 | Auspex Pharmaceutical Inc | Composto e composição farmacêutica |
AR074776A1 (es) * | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
UA108077C2 (xx) * | 2009-07-02 | 2015-03-25 | Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну | |
WO2011009075A2 (en) | 2009-07-17 | 2011-01-20 | Rigel Pharmaceuticals, Inc. | Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
WO2011063241A1 (en) | 2009-11-20 | 2011-05-26 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
MA33909B1 (fr) | 2009-12-23 | 2013-01-02 | Takeda Pharmaceutical | Pyrrolidinones accoles en tant d'inhibiteurs de syk |
US20110206661A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Trimethoxyphenyl inhibitors of tyrosine kinase |
JP6067550B2 (ja) | 2010-04-13 | 2017-01-25 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用 |
IL223022A0 (en) | 2010-05-14 | 2013-02-03 | Texas A & M Univ Sys | Functional, cross-linked nanostructures for tandem optical imaging and therapy |
BR112013003388A2 (pt) | 2010-08-10 | 2016-07-12 | Celgene Avilomics Res Inc | sal de besilato de um inibidor de btk |
MX2013004894A (es) | 2010-11-01 | 2013-10-17 | Celgene Avilomics Res Inc | Compuestos heterociclicos y usos de los mismos. |
US9238629B2 (en) | 2010-11-01 | 2016-01-19 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
UY34072A (es) | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
EP2723739B1 (en) | 2011-06-22 | 2016-08-24 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
CA2843138C (en) * | 2011-07-28 | 2020-06-02 | Rigel Pharmaceuticals, Inc. | New (trimethoxyphenylamino)pyrimidinyl formulations |
EP2770830A4 (en) | 2011-10-28 | 2015-05-27 | Celgene Avilomics Res Inc | METHODS OF TREATING A DISEASE OR DISEASE ASSOCIATED WITH TYROSINE KINASE BTK (BRUTON'S TYROSINE KINASE) |
US9073944B2 (en) * | 2012-02-21 | 2015-07-07 | Merck Patent Gmbh | Cyclic diaminopyrimidine derivatives |
CA2866852C (en) | 2012-03-15 | 2020-12-29 | Celgene Avilomics Research, Inc. | Solid forms of an epidermal growth factor receptor kinase inhibitor |
US9108927B2 (en) | 2012-03-15 | 2015-08-18 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
MX356695B (es) | 2012-06-19 | 2018-06-11 | Debiopharm Int Sa | Profarmacos derivados de (e)-n-metil-n-((3-metilbenzofuran-2-il)me til)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il) acrilamida. |
CN102746337B (zh) * | 2012-06-21 | 2014-12-17 | 成都苑东药业有限公司 | 一种2,4-嘧啶二胺类化合物及其制备方法 |
BR112015005894B1 (pt) | 2012-09-18 | 2022-03-29 | Auspex Pharmaceuticals, Inc | Composto, composição farmacêutica, método para tratar um distúrbio mediado por vmat2 e formulação farmacêutica de liberação prolongada |
US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
WO2014100748A1 (en) | 2012-12-21 | 2014-06-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
MX2015009952A (es) | 2013-02-08 | 2015-10-05 | Celgene Avilomics Res Inc | Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos. |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
MX369956B (es) | 2013-12-03 | 2019-11-27 | Auspex Pharmaceuticals Inc | Metodos para preparar compuestos de benzoquinolina. |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
LT3083648T (lt) * | 2013-12-20 | 2019-01-25 | Rigel Pharmaceuticals, Inc. | Farmacinis būdas ir tarpiniai junginiai |
US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
CN114796209A (zh) | 2015-03-06 | 2022-07-29 | 奥斯拜客斯制药有限公司 | 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物 |
KR20180114177A (ko) | 2016-02-26 | 2018-10-17 | 데비오팜 인터네셔날 에스 에이 | 당뇨병성 족부 감염의 치료제 |
ES2970382T3 (es) | 2019-08-14 | 2024-05-28 | Rigel Pharmaceuticals Inc | Método para bloquear o mejorar el síndrome de liberación de citocinas |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
IE66203B1 (en) | 1989-12-04 | 1995-12-13 | Searle & Co | System for transdermal albuterol administration |
US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
JPH07502219A (ja) | 1991-12-18 | 1995-03-09 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 多重層型バリアー構造体 |
EP0553769B1 (de) | 1992-01-29 | 1996-01-03 | FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG | Ballspielschläger, insbesondere Tennisschläger |
IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CN103169708B (zh) | 2002-07-29 | 2018-02-02 | 里格尔药品股份有限公司 | 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
RS53109B (en) * | 2003-07-30 | 2014-06-30 | Rigel Pharmaceuticals Inc. | 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES |
US7149693B2 (en) | 2003-07-31 | 2006-12-12 | Sony Corporation | Automated digital voice recorder to personal information manager synchronization |
CA2578349A1 (en) * | 2004-09-01 | 2006-03-16 | Rigel Pharmaceuticals, Inc. | Synthesis of 2,4-pyrimidinediamine compounds |
ATE540035T1 (de) * | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
ES2337496T3 (es) | 2005-01-19 | 2010-04-26 | Rigel Pharmaceuticals, Inc. | Profarmacos de compuestos de 2,4-pirimidindiamina y sus usos. |
CA2604551A1 (en) * | 2005-05-03 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Jak kinase inhibitors and their uses |
NZ563454A (en) * | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP1896134A2 (en) * | 2005-06-13 | 2008-03-12 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
WO2007053844A2 (en) * | 2005-10-31 | 2007-05-10 | Rigel Pharmaceuticals, Inc. | Compositions and methods for treating inflammatory disorders |
US7713987B2 (en) * | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
CA2642211C (en) * | 2006-02-17 | 2012-01-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
EP1991532B1 (en) * | 2006-02-24 | 2017-01-11 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
CA2673125C (en) * | 2006-10-19 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
ES2380551T3 (es) | 2006-11-21 | 2012-05-16 | Rigel Pharmaceuticals, Inc. | Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos |
WO2008118822A1 (en) * | 2007-03-23 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2008118823A2 (en) * | 2007-03-26 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2009012421A1 (en) | 2007-07-17 | 2009-01-22 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
CA2843138C (en) * | 2011-07-28 | 2020-06-02 | Rigel Pharmaceuticals, Inc. | New (trimethoxyphenylamino)pyrimidinyl formulations |
-
2007
- 2007-11-20 ES ES07864696T patent/ES2380551T3/es active Active
- 2007-11-20 WO PCT/US2007/085313 patent/WO2008064274A1/en active Application Filing
- 2007-11-20 AT AT07864696T patent/ATE540041T1/de active
- 2007-11-20 JP JP2009538501A patent/JP5264759B2/ja active Active
- 2007-11-20 DK DK07864696.5T patent/DK2078026T3/da active
- 2007-11-20 CA CA2673137A patent/CA2673137C/en active Active
- 2007-11-20 EP EP07864696A patent/EP2078026B1/en active Active
- 2007-11-20 EP EP11187930A patent/EP2420505A1/en not_active Withdrawn
- 2007-11-20 US US11/943,506 patent/US8163902B2/en active Active
-
2010
- 2010-01-11 HK HK10100267.4A patent/HK1133257A1/xx unknown
-
2012
- 2012-03-12 US US13/418,306 patent/US8445485B2/en active Active
-
2013
- 2013-04-12 US US13/861,650 patent/US8912170B2/en active Active
-
2014
- 2014-11-06 US US14/534,784 patent/US9283238B2/en active Active - Reinstated
-
2016
- 2016-01-25 US US15/005,771 patent/US9737554B2/en not_active Ceased
-
2017
- 2017-07-17 US US15/651,687 patent/US10357505B2/en active Active
-
2019
- 2019-03-04 US US16/291,992 patent/USRE48898E1/en active Active
- 2019-06-12 US US16/438,972 patent/US20200016179A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8912170B2 (en) | 2014-12-16 |
ATE540041T1 (de) | 2012-01-15 |
US20130310341A1 (en) | 2013-11-21 |
USRE48898E1 (en) | 2022-01-25 |
EP2420505A1 (en) | 2012-02-22 |
US20200016179A1 (en) | 2020-01-16 |
US20150133404A1 (en) | 2015-05-14 |
WO2008064274A1 (en) | 2008-05-29 |
CA2673137C (en) | 2015-02-10 |
EP2078026A1 (en) | 2009-07-15 |
US20110144059A1 (en) | 2011-06-16 |
CA2673137A1 (en) | 2008-05-29 |
DK2078026T3 (da) | 2012-04-30 |
ES2380551T3 (es) | 2012-05-16 |
JP2010510322A (ja) | 2010-04-02 |
US20120208785A1 (en) | 2012-08-16 |
US20160367575A1 (en) | 2016-12-22 |
US8445485B2 (en) | 2013-05-21 |
US9737554B2 (en) | 2017-08-22 |
US20180153912A1 (en) | 2018-06-07 |
JP5264759B2 (ja) | 2013-08-14 |
US9283238B2 (en) | 2016-03-15 |
US10357505B2 (en) | 2019-07-23 |
US8163902B2 (en) | 2012-04-24 |
EP2078026B1 (en) | 2012-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1133257A1 (zh) | ||
HUS2000011I1 (hu) | A 2,4-pirimidin-diamin vegyületek elõgyógyszerei és alkalmazásuk | |
UA105778C2 (uk) | Піразол-4-n-алкоксикарбоксаміди як мікробіоциди, композиція, що їх містить, та спосіб боротьби із зараженням корисних рослин фітопагенними мікроорганізмами або його попередження з їх використанням | |
TW200716558A (en) | Heteroaroyl-substituted serineamides | |
TW200612958A (en) | Substituted imidazole derivatives | |
MY140841A (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
IN2014MN00380A (zh) | ||
MX2009005616A (es) | Derivados de pirido-pirazina utiles como compuestos herbicidas. | |
UA102514C2 (ru) | Производные иминопиридина, промежуточное соединение, способ борьбы с заражением полезных растений грибами или его предупреждение и композиция на основе производной иминопиридина | |
UA94052C2 (uk) | Похідні піридазину | |
EP3586631A3 (en) | Plant health composition | |
MY157871A (en) | Mapk/erk kinase inhibitors | |
AU2008255733A8 (en) | Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity | |
TW200800951A (en) | Substituted imidazole compounds as KSP inhibitors | |
MY151295A (en) | Pyrimidyl indoline compound | |
MY139522A (en) | New alkyl-pyridines as 11-beta inhibitors for diabetes | |
TW200745097A (en) | 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors | |
UA96759C2 (en) | 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS | |
UA105022C2 (uk) | Композиція для боротьби з хворобами рослин та спосіб боротьби з хворобами рослин | |
MY156678A (en) | Pest controlling composition and method of controlling pest | |
WO2011009075A3 (en) | Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses | |
TW200724168A (en) | Pharmaceutical compositions | |
TW200732286A (en) | Ester compound and its use | |
UA102215C2 (ru) | Отверждающие агенты для эпоксифункциональных соединений | |
UA101419C2 (ru) | Композиция и способ для борьбы с болезнями растений |